The iShares U.S. Healthcare ETF (IYH) posted an 18.7% year-to-date return through July 2026, according to data from finance.yahoo.com. This performance has renewed investor scrutiny on how the diversified IYH stacks up against the more concentrated VanEck Biotech ETF (BBH) for capturing long-term healthcare sector growth. The comparison is critical for institutional portfolios reassessing their strategic allocations to defensive sectors amid ongoing economic crosscurrents.
Context — [why comparing healthcare ETFs matters now]
The current macroeconomic environment of moderated inflation and a stable but elevated rate outlook has renewed interest in the defensive characteristics of healthcare. Historically, healthcare has exhibited low correlation to economic cycles, outperforming the broader S&P 500 during recessions, as it did by 13.2% in the 2008 downturn. The current catalyst for the sector's strong 2026 performance is a surge in pharmaceutical and biotech merger and acquisition activity. This deal flow, exceeding $120 billion in the first half of 2026, was driven by patent cliffs and a need for large-cap pharma to replenish pipelines.
Investors are also rotating capital towards sectors with predictable cash flows as growth expectations elsewhere moderate. The sector's resilience is also tied to demographic tailwinds from an aging global population. This backdrop makes the choice between a broad-based fund and a thematic biotech fund a significant portfolio decision. The decision hinges on risk tolerance and conviction in the near-term innovation cycle.
Data — [what the numbers show]
Concrete performance data reveals a clear divergence in strategy and results. The iShares U.S. Healthcare ETF (IYH) held assets of $4.2 billion as of July 2026, with an expense ratio of 0.39%. Its year-to-date return of 18.7% through early July 2026 compares to a 14.1% gain for the SPDR S&P Biotech ETF (XBI). In contrast, the VanEck Biotech ETF (BBH) has a much smaller asset base of $840 million and a higher expense ratio of 0.35%.
The key differentiator is portfolio concentration. IYH provides diversified exposure across the healthcare ecosystem.
| Metric | IYH | BBH |
|---|
| Top 10 Holdings % | ~55% | ~75% |
| Number of Holdings | 116 | 25 |
| Pharma/Biotech Weight | ~45% | ~98% |
IYH's top holdings include UnitedHealth Group (12.1% weight) and Johnson & Johnson (11.5%), while BBH is dominated by Eli Lilly (15.2%) and Vertex Pharmaceuticals (12.8%). This structural difference leads to higher volatility for BBH, evidenced by its 5-year standard deviation of 28.5 versus IYH's 18.1.
Analysis — [what it means for markets / sectors / tickers]
The choice between these ETFs creates distinct second-order effects for underlying holdings. A large flow into IYH disproportionately benefits mega-cap, diversified healthcare giants like UnitedHealth Group (UNH) and Johnson & Johnson (JNJ). These firms gain from both direct weighting and the perception of stable, defensive capital. Conversely, capital favoring BBH flows directly into pure-play biotech names like Regeneron (REGN) and Alnylam Pharmaceuticals (ALNY), potentially boosting their valuations independent of individual pipeline news.
A key limitation of the BBH strategy is its extreme dependence on a handful of successful firms. Clinical trial failures for top constituents like Vertex or BioMarin could trigger outsized losses not easily offset by other holdings. The IYH structure mitigates this single-stock risk but may dilute exposure to explosive biotech breakthroughs. Current positioning data shows institutional money market funds rotating a portion of assets into broad healthcare ETFs like IYH for stability. Hedge funds and venture capital arms are more active in the concentrated biotech space, using vehicles like BBH for tactical, high-conviction bets.
Outlook — [what to watch next]
Two immediate catalysts will determine the near-term trajectory for both funds. The Q2 2026 earnings season, beginning in mid-July, will test the pricing power and margin resilience of IYH's managed care and device holdings. For BBH, the primary watchpoint is the PDUFA date for a key sickle cell disease therapy decision on August 15, 2026, which will directly impact a top-10 holding.
Technical levels to monitor include IYH's 200-day moving average at $385.50, which has acted as strong support. For BBH, a close above its 52-week high of $215.75 would signal a potential breakout. The direction of the 10-year Treasury yield, currently at 4.2%, remains a crucial macro input. Yields stabilizing or falling further would enhance the relative appeal of growth-sensitive biotech stocks, potentially benefiting BBH.
Frequently Asked Questions
Which healthcare ETF is better for dividend income?
The iShares U.S. Healthcare ETF (IYH) is the superior choice for dividend seekers. Its diversified portfolio includes large, mature pharmaceuticals and managed care companies with established dividend policies. IYH's current 30-day SEC yield is approximately 1.4%, derived from holdings like Johnson & Johnson and Pfizer. The VanEck Biotech ETF (BBH) focuses on growth and reinvestment, resulting in a negligible dividend yield below 0.2%, as most biotech firms do not pay dividends.
How does the 2026 M&A wave affect IYH and BBH differently?
The 2026 surge in pharmaceutical M&A activity provides a more direct and concentrated boost to the VanEck Biotech ETF (BBH). As an acquirer targets a biotech firm, that firm's stock price typically appreciates sharply. BBH's concentrated holdings in mid-to-large-cap biotech names make it more likely to hold an acquisition target. IYH benefits indirectly, as its pharmaceutical holdings may be the acquirers, with gains moderated by the acquisition cost and integration risks.
What is the historical performance difference between these ETFs in a bear market?
Historically, the iShares U.S. Healthcare ETF (IYH) has demonstrated stronger defensive characteristics during market downturns. In the 2022 bear market, when the S&P 500 fell 19.4%, IYH declined by 8.2%. The VanEck Biotech ETF (BBH), with its higher beta and growth focus, fell 15.1% over the same period. This performance gap highlights IYH's stability during risk-off periods due to its exposure to non-cyclical healthcare services and essential pharmaceuticals.
Bottom Line
For long-term, risk-adjusted exposure to healthcare, the diversified IYH offers a more stable and defensive profile than the concentrated biotech bet of BBH.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
